These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 32081238)

  • 1. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
    Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
    JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
    Gouëffic Y; Kaladji A; Guyomarch B; Montagne C; Fairier D; Gestin S; Riche VP; Vent PA; Chaillou P; Costargent A; Patra P
    Trials; 2014 Oct; 15():423. PubMed ID: 25359394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
    Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
    J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
    Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
    J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
    Ichihashi S; Shibata T; Fujimura N; Nagatomi S; Yamamoto H; Kyuragi R; Adachi A; Iwakoshi S; Bolstad F; Saeki K; Obayashi K; Kichikawa K
    J Endovasc Ther; 2019 Oct; 26(5):613-620. PubMed ID: 31257994
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery.
    Miura T; Miyashita Y; Soga Y; Hozawa K; Doijiri T; Ikeda U; Kuwahara K;
    Circ Cardiovasc Interv; 2018 Aug; 11(8):e006564. PubMed ID: 30354784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bare Metal Versus Paclitaxel-Eluting Stents for Long Femoropopliteal Lesions: Prospective Cohorts Comparison Using a Propensity Score-Matched Analysis.
    Vent PA; Kaladji A; Davaine JM; Guyomarch B; Chaillou P; Costargent A; Quillard T; Gouëffic Y
    Ann Vasc Surg; 2017 Aug; 43():166-175. PubMed ID: 28300676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
    Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
    JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
    Dake MD; Scheinert D; Tepe G; Tessarek J; Fanelli F; Bosiers M; Ruhlmann C; Kavteladze Z; Lottes AE; Ragheb AO; Zeller T;
    J Endovasc Ther; 2011 Oct; 18(5):613-23. PubMed ID: 21992630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
    Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
    Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
    J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel exposure and long-term mortality of patients treated with the Zilver PTX drug-eluting stent.
    Stern JR; Tran K; Chandra V; Harris EJ; Lee JT
    Vascular; 2021 Aug; 29(4):567-573. PubMed ID: 33054678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
    Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
    Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
    Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
    J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions.
    Katsuki T; Takahara M; Soga Y; Okamoto S; Iida O; Fujihara M; Kawasaki D; Ando K
    J Endovasc Ther; 2019 Oct; 26(5):593-599. PubMed ID: 31431154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
    Brodmann M; Keirse K; Scheinert D; Spak L; Jaff MR; Schmahl R; Li P; Zeller T;
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2113-2123. PubMed ID: 29050631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Zilver PTX eluting stent in TASC C/D lesions and restenosis.
    Leopardi M; Houbballah R; Becquemin JP
    J Cardiovasc Surg (Torino); 2014 Apr; 55(2):229-34. PubMed ID: 24670831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single center experience of Zilver PTX for femoro-popliteal lesions.
    Kang WY; Campia U; Didier RJ; Kiramijyan S; Koifman E; Negi SI; Lipinski MJ; Baker NC; Escarcega RO; Torguson R; Waksman R; Bernardo NL
    Cardiovasc Revasc Med; 2016 Sep; 17(6):399-403. PubMed ID: 27496591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.